| HOME >> MEDICINE >> TECHNOLOGY |
42-Total product sales
$ 3,618$ 3,528U.S.$ 2,778$ 2,677International
840851Total product sales
$ 3,618$ 3,528Amgen Inc.Condensed Consolidated Balance Sheets - GAAP(In millions)(Unaudited)March 31, December 31,20112010AssetsCurrent assets:Cash, cash equivalents and marketable securities
$
5,358$
7,422Trade receivables, net
2,5172,335Inventories
2,0982,022Other current assets
1,7161,350Total current assets
21,68923,129Property, plant and equipment, net
5,4555,522Intangible assets, net
2,8082,230Goodwill
11,50411,334Other assets
1,2581,271Total assets
$
42,714$
43,486Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued liabilities
$
4,166$
4,082Current portion of convertible notes
832,488Total current liabilities
4,2496,570Convertible notes
2,2462,296Other long-term debt
8,5788,578Other non-current liabilities
2,6572,098Stockholders' equity
24,98423,944Total liabilities and stockholders' equity
$
42,714$
43,486Shares outstanding
933932Amgen Inc.Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt Outstanding(In millions)(Unaudited)March 31, 2011GAAPAdjustments for
accounting
standard"Adjusted"Total debt outstanding
$ 10,907$
254
(a) $ 11,161(a)To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.Amgen Inc.Reconciliation of GAAP EPS Guidance to "Adjusted"EPS Guidance for the Year Ending December 31, 2011(Unaudited)On April 20, 2011, the Company reaffirmed its “Adjusted” EPS guidance to be in the range of $5.00 to $5.20.The following table shows a reconciliation of GAAP EPS (diluted) guidance to “Adjusted” EPS (diluted) guidance.2011GAAP EPS (diluted) guidance$ 4.56
-
$ 4.79Known adju
'/>"/>
| SOURCE Amgen Copyright©2010 PR Newswire. All rights reserved |